Indication
B-cell Non-Hodgkin's Lymphoma
10 clinical trials
8 products
3 drugs
Clinical trial
A Phase Ib/II Study of SHR-A1912 Combined With Other Therapies in Patients With B-cell Non-Hodgkin 's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
SHR-A1912Clinical trial
A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)Status: Not yet recruiting, Estimated PCD: 2025-05-20
Product
RJMty19Product
MB-CART20.1Clinical trial
A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART20.1 in Patients With Relapsed or Resistant CD20 Positive B-NHLStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-Expressing Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Product
XmAb13676Product
TazemetostatClinical trial
A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationStatus: Completed, Estimated PCD: 2021-12-17
Product
BAFFR-CAR T cellsClinical trial
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)Status: Recruiting, Estimated PCD: 2027-07-13
Clinical trial
A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2017-07-12
Clinical trial
A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2021-01-13
Product
Debio 1562Drug
VarlilumabClinical trial
A Phase I, Open-Label, Dose-escalation, Multicentre Study of KW-2478 Administered as a Single Agent Intravenously in a Consecutive Dosing Schedule in Patients With Relapsed/Refractory Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2010-08-01
Product
KW-2478Clinical trial
A Phase Ib/IIa Clinical Study of IMM0306 fo r Injection in Combination With Lenalidomide for the Treatment of Relapsed/Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma Cell Non-Hodgkin's LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Drug
IMM0306Drug
lenalidomide